Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avalon GloboCare ( (ALBT) ) just unveiled an update.
On February 2, 2026, Avalon GloboCare Corp. announced it had converted $2.6 million of its $2.8 million in institutional investor debentures from a June 2024 financing into common stock, after repaying $288,000 in cash, thereby eliminating the majority of its outstanding debt. The company said the move removes a significant balance-sheet overhang, improves financial transparency, reinforces its recently regained compliance with Nasdaq’s minimum stockholders’ equity requirement, and enhances financial flexibility as it pursues its diagnostic, intellectual property, and AI-driven growth initiatives, with management indicating that substantially all of the converted shares have already been sold.
More about Avalon GloboCare
Avalon GloboCare Corp. (NASDAQ: ALBT) is a diversified company focused on precision diagnostic consumer products and the development of intellectual property in generative artificial intelligence publishing and software. The company currently markets the KetoAir™ breathalyzer, registered with the U.S. Food and Drug Administration as a Class I medical device, plans additional diagnostic applications for its breathalyzer technology, continues to build its patent portfolio, and also owns and operates commercial real estate.
Average Trading Volume: 220,027
Technical Sentiment Signal: Sell
Current Market Cap: $3.58M
See more insights into ALBT stock on TipRanks’ Stock Analysis page.